Sanofi ADR (NASDAQ: SNY) has a higher price-to-earnings ratio of 20.53x compared to its average ratio, The 36-month beta value for SNY is at 0.61. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SNY is 2.50B, and currently, shorts hold a 0.16% of that float. The average trading volume for SNY on April 24, 2024 was 1.98M shares.
SNY) stock’s latest price update
Sanofi ADR (NASDAQ: SNY)’s stock price has soared by 1.15 in relation to previous closing price of 47.15. Nevertheless, the company has seen a gain of 4.13% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-23 that Sanofi’s (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
SNY’s Market Performance
Sanofi ADR (SNY) has seen a 4.13% rise in stock performance for the week, with a -0.79% decline in the past month and a -4.41% plunge in the past quarter. The volatility ratio for the week is 1.90%, and the volatility levels for the past 30 days are at 1.66% for SNY.. The simple moving average for the past 20 days is 0.65% for SNY’s stock, with a -4.71% simple moving average for the past 200 days.
Analysts’ Opinion of SNY
Many brokerage firms have already submitted their reports for SNY stocks, with Morgan Stanley repeating the rating for SNY by listing it as a “Equal-Weight.” The predicted price for SNY in the upcoming period, according to Morgan Stanley is $55 based on the research report published on January 23, 2024 of the current year 2024.
SNY Trading at 0.40% from the 50-Day Moving Average
After a stumble in the market that brought SNY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.52% of loss for the given period.
Volatility was left at 1.66%, however, over the last 30 days, the volatility rate increased by 1.90%, as shares sank -3.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.56% upper at present.
During the last 5 trading sessions, SNY rose by +4.13%, which changed the moving average for the period of 200-days by -7.04% in comparison to the 20-day moving average, which settled at $47.30. In addition, Sanofi ADR saw -4.10% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SNY
Current profitability levels for the company are sitting at:
- 0.22 for the present operating margin
- 0.66 for the gross margin
The net margin for Sanofi ADR stands at 0.14. The total capital return value is set at 0.12. Equity return is now at value 7.22, with 4.25 for asset returns.
Based on Sanofi ADR (SNY), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at 1.02. The debt to equity ratio resting at 0.23. The interest coverage ratio of the stock is 12.3.
Currently, EBITDA for the company is 12.96 billion with net debt to EBITDA at 0.59. When we switch over and look at the enterprise to sales, we see a ratio of 2.12. The receivables turnover for the company is 5.17for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.27.
Conclusion
In conclusion, Sanofi ADR (SNY) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
